Analyst price targets for these two biotechs suggest they could double your money. Here’s what you need to know.
A handful of investment-bank analysts think Chimerix, Inc. (NASDAQ:CMRX), and Aclaris Therapeutics (NASDAQ:ACRS) have what it takes to more than double your money. It’s not unusual for biotech stocks to deliver huge gains, but there’s always a lot that can go wrong along the way.
To help you decide if any of these small-cap players are worth the risk, here’s what you need to know about the opportunities and challenges they’re facing right now.
